Lv73
3520 积分 2023-02-22 加入
Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML)
19天前
已完结
Safety and efficacy of imatinib in CML over a period of 10 years: data from the randomized CML-study IV
19天前
已完结
Deep Molecular Response Is Reached by the Majority of Patients Treated With Imatinib, Predicts Survival, and Is Achieved More Quickly by Optimized High-Dose Imatinib: Results From the Randomized CML-Study IV
20天前
已完结
How I manage relapse of chronic myeloid leukaemia after stopping tyrosine kinase inhibitor therapy
25天前
已完结
Transplant to treatment-free remission: the evolving view of 'cure' in chronic myeloid leukemia
25天前
已完结
Transplant to treatment-free remission: the evolving view of 'cure' in chronic myeloid leukemia
25天前
已关闭
血液病/恶性肿瘤患者侵袭性真菌病的诊断标准与治疗原则
1个月前
已完结
Real-world comparison of flumatinib and nilotinib as first-line therapy for patients with chronic phase chronic myeloid leukemia: a multicenter retrospective study
1个月前
已完结
皖公网安备34019202002308
